Drugs / AX-8
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04107441 | Sep 2019 → Feb 2020 | — | Axalbion SA | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04866563 | Aug 2021 → Jun 2025 | — | Axalbion SA | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-05-22 | Axalbion SA | Results Press Release – Axalbion Presented Promising Phase 2 Clinical Data in Chronic Cough with AX-8, a Novel TRPM8 Agonist, in an Oral Presentation at the American Thoracic Society (ATS) 2023 International Conference axalbion.com ↗
Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, presented positive results from a Phase 2 proof-of-concept study with its transient receptor potential melastatin 8 (TRPM8) agonist, AX-8, in patients with refractory or unexplained chronic cough, in an oral session at the American Thoracic Society (ATS) 2023 International Conference, being held in Washington, DC, from May 19 – 24, 2023. |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AX-8 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04107441 ↗ |
| Route | Oral | “AX-8 ODTs will be administered orally and will be dissolved on the back of the tongue” NCT04107441 ↗ |